Please assess the completion status of the following clinical trial:

Trial Title: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven adenocarcinoma of the rectum, the lower pole less than 15 cm from the anal verge~* Patient should not have receive any treatment for cancer~* Synchronous metastases with unresectable hepatic and/or lung localization or uncertain resectability (potentially resectable)~* Measurable lesions by RECIST 1.1 (metastasis and primary cancer of the rectum)~* Age ≥ 18 years~* WHO ≤ 2~* ANC ≥ 1.5 x 10 9/L, platelets ≥ 100 x 10 9/L, creatinine clearance ≥ 60 mL/min~* Hemoglobin ≥ 10 g /dL~* Signed informed consent~Exclusion Criteria:~* Rectal Cancer in occlusion requiring surgery or a prosthesis in emergency~* Rectal bleeding severe and active~* Prior pelvic irradiation~* History of cancer, except non-melanoma skin cancer, carcinoma in situ of the cervix treated curatively and other cancers treated curatively if they do not relapse over 3 years,~* Hepatic impairment (total bilirubin\> 1.5 x upper limit of normal (ULN) and serum albumin \<25g / L); known Gilbert's disease~* Uncontrolled severe infection,~* Severe pain (VAS\> 5/10) uncontrollable by opioid therapy~* Symptomatic sensorimotor peripheral neuropathy~* Pregnant or lactating patients or patient of both sexes with childbearing potential and not using adequate contraception method~* Patient receiving or having received an experimental therapy within 4 weeks prior to enter into the study or participating in another clinical study of other experimental drugs~* Known hypersensitivity to any component of the treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- single arm study/ non randomized trial (Type: OTHER): FOLFORINOX

Based on this trial design, predict the completion outcome and termination type (if applicable).